Wason

Efficient adaptive designs for clinical trials of interventions for COVID-19

*Statistics in Biopharmaceutical Research* 2020; 12(4):483-497

Including non-concurrent control patients in the analysis of platform trials: Is it worth it?

*BMC Medical Research Methodology* 2020; 20:165

Graphical approaches for the control of generalised error rates

*Statistics in Medicine* 2020

The Adaptive designs CONSORT Extension (ACE) statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

*BMJ* 2020; 369:m115

Analysis of responder-based endpoints: improving power through utilising continuous components

*Trials* 2020; 21:427

Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy

*Biostatistics* 2020

Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): 5-year follow-up of a pragmatic, randomised, controlled, superiority trial

*Lancet Psychiatry* 2020; 7(5):P420-P430

Two-stage sparse regression screening to detect biomarker-treatment interactions in randomized clinical trials

*arXiv* 2020; arXiv:2004.12028

Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): Study protocol for a randomised controlled trial

*BMJ Open* 2020; 10(4):e035947

Prevalence of multiplicity and appropriate adjustments among cardiovascular randomized clinical trials published in major medical journals

*JAMA Network Open* 2020; 3(4):e203082